Preemptive Pharmacogenomic Testing for Precision Medicine

Significant barriers, such as lack of professional guidelines, specialized training for interpretation of pharmacogenomics (PGx) data, and insufficient evidence to support clinical utility, prevent preemptive PGx testing from being widely clinically implemented. The current study, as a pilot project for the Right Drug, Right Dose, Right Time–Using Genomic Data to Individualize Treatment Protocol, was designed to evaluate the impact of preemptive PGx and to optimize the workflow in the clinic setting.

Source: Journal of Molecular Diagnostics - March 3, 2016 Category: Pathology Authors: Yuan Ji, Jennifer M. Skierka, Joseph H. Blommel, Brenda E. Moore, Douglas L. VanCuyk, Jamie K. Bruflat, Lisa M. Peterson, Tamra L. Veldhuizen, Numrah Fadra, Sandra E. Peterson, Susan A. Lagerstedt, Laura J. Train, Linnea M. Baudhuin, Eric W. Klee, Matthew Tags: Regular Article Source Type: research